Free Trial

Amgen (AMGN) Financials

Amgen logo
$279.45 +7.79 (+2.87%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$279.52 +0.06 (+0.02%)
As of 04:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Amgen

Annual Income Statements for Amgen

This table shows Amgen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
4,090 6,717 6,552 5,893 7,264 7,842 8,394 1,979 7,722 6,939
Consolidated Net Income / (Loss)
4,090 6,717 6,552 5,893 7,264 7,842 8,394 1,979 7,722 6,939
Net Income / (Loss) Continuing Operations
4,090 6,717 6,552 5,893 7,264 7,842 8,394 1,979 7,722 6,939
Total Pre-Tax Income
4,609 7,855 7,346 6,701 8,133 9,138 9,545 9,597 9,163 7,978
Total Operating Income
7,258 7,897 9,566 7,639 9,139 9,674 10,263 9,973 9,794 8,470
Total Gross Profit
20,566 19,739 19,917 19,525 19,265 19,006 19,646 18,780 18,829 17,435
Total Revenue
33,424 28,190 26,323 25,979 25,424 23,362 23,747 22,849 22,991 21,662
Total Cost of Revenue
12,858 8,451 6,406 6,454 6,159 4,356 4,101 4,069 4,162 4,227
Operating Cost of Revenue
12,858 8,451 6,406 6,454 6,159 4,356 4,101 4,069 4,162 4,227
Total Operating Expenses
13,308 11,842 10,351 11,886 10,126 9,332 9,383 8,807 9,035 8,965
Selling, General & Admin Expense
7,344 7,058 5,917 5,562 5,919 5,216 5,646 5,245 5,195 4,895
Research & Development Expense
5,964 4,784 4,434 6,324 4,207 4,116 3,737 3,562 3,840 4,070
Total Other Income / (Expense), net
-2,649 -42 -2,220 -938 -1,006 -536 -718 -376 -631 -492
Interest Expense
3,155 2,875 1,406 1,197 1,262 1,289 1,392 1,304 1,260 1,095
Other Income / (Expense), net
506 2,833 -814 259 256 753 674 928 629 603
Income Tax Expense
519 1,138 794 808 869 1,296 1,151 7,618 1,441 1,039
Basic Earnings per Share
$7.62 $12.56 $12.18 $10.34 $12.40 $12.96 $12.70 $2.71 $10.32 $9.15
Weighted Average Basic Shares Outstanding
537M 535M 538M 570M 586M 605M 661M 731M 748M 758M
Diluted Earnings per Share
$7.56 $12.49 $12.11 $10.28 $12.31 $12.88 $12.62 $2.69 $10.24 $9.06
Weighted Average Diluted Shares Outstanding
541M 538M 541M 573M 590M 609M 665M 735M 754M 766M
Weighted Average Basic & Diluted Shares Outstanding
537.20M 535.92M 533.98M 557.03M 577.57M 589.81M 660.90M 730.30M 748.30M 758.40M
Cash Dividends to Common per Share
$9.13 - - $7.04 $6.40 $5.80 $5.28 $4.60 $4.00 $3.16

Quarterly Income Statements for Amgen

This table shows Amgen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
1,730 627 2,830 746 -113 767 1,730 1,379 2,841 1,616 2,143
Consolidated Net Income / (Loss)
1,730 627 2,830 746 -113 767 1,730 1,379 2,841 1,616 2,143
Net Income / (Loss) Continuing Operations
1,730 627 2,830 746 -113 767 1,730 1,379 2,841 1,616 2,143
Total Pre-Tax Income
1,973 782 3,101 794 -68 852 1,947 1,614 3,442 1,748 2,392
Total Operating Income
1,178 2,311 2,047 1,909 991 1,271 2,021 2,684 1,921 2,230 2,660
Total Gross Profit
5,181 5,974 5,193 5,152 4,247 5,084 5,097 5,173 4,385 5,092 5,064
Total Revenue
8,149 9,086 8,503 8,388 7,447 8,196 6,903 6,986 6,105 6,839 6,652
Total Cost of Revenue
2,968 3,112 3,310 3,236 3,200 3,112 1,806 1,813 1,720 1,747 1,588
Operating Cost of Revenue
2,968 3,112 3,310 3,236 3,200 3,112 1,806 1,813 1,720 1,747 1,588
Total Operating Expenses
4,003 3,663 3,146 3,243 3,256 3,813 3,076 2,489 2,464 2,862 2,404
Selling, General & Admin Expense
2,517 2,126 1,625 1,785 1,808 3,153 1,353 1,294 1,258 2,075 1,287
Research & Development Expense
1,486 1,724 1,450 1,447 1,343 1,534 1,079 1,113 1,058 1,324 1,112
Total Other Income / (Expense), net
795 -1,529 1,054 -1,115 -1,059 -419 -74 -1,070 1,521 -482 -268
Interest Expense
723 747 776 808 824 821 759 752 543 415 368
Other Income / (Expense), net
1,518 -782 1,830 -307 -235 402 685 -318 2,064 -67 100
Income Tax Expense
243 155 271 48 45 85 217 235 601 132 249
Basic Earnings per Share
$3.22 $1.17 $5.27 $1.39 ($0.21) $1.43 $3.23 $2.58 $5.32 $3.02 $4.01
Weighted Average Basic Shares Outstanding
538M 537M 537M 537M 536M 535M 535M 535M 534M 538M 535M
Diluted Earnings per Share
$3.20 $1.17 $5.22 $1.38 ($0.21) $1.42 $3.22 $2.57 $5.28 $3.00 $3.98
Weighted Average Diluted Shares Outstanding
541M 541M 542M 541M 536M 538M 538M 537M 538M 541M 538M
Weighted Average Basic & Diluted Shares Outstanding
537.71M 537.20M 537.53M 537.33M 536.43M 535.92M 535.18M 534.90M 534.33M 533.98M 533.58M
Cash Dividends to Common per Share
$2.38 - $2.25 - $2.25 - $2.13 - $2.13 - $1.94

Annual Cash Flow Statements for Amgen

This table details how cash moves in and out of Amgen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
1,029 3,315 -360 1,723 229 -908 3,145 559 -903 413
Net Cash From Operating Activities
11,490 8,471 9,721 9,261 10,497 9,150 11,296 11,177 10,354 9,731
Net Cash From Continuing Operating Activities
11,490 8,471 9,721 9,261 10,497 8,842 11,296 10,509 10,354 9,731
Net Income / (Loss) Continuing Operations
4,090 6,717 6,552 5,893 7,264 7,842 8,394 1,979 7,722 6,939
Consolidated Net Income / (Loss)
4,090 6,717 6,552 5,893 7,264 7,842 8,394 1,979 7,722 6,939
Depreciation Expense
5,592 4,071 3,417 3,398 3,601 2,206 1,946 1,955 2,105 2,108
Non-Cash Adjustments To Reconcile Net Income
671 -560 1,683 1,617 135 -186 697 663 343 176
Changes in Operating Assets and Liabilities, net
1,137 -1,757 -1,931 -1,647 -503 -1,020 259 6,580 184 508
Net Cash From Investing Activities
-1,046 -26,204 -6,044 733 -5,401 5,709 14,339 -4,024 -8,658 -5,547
Net Cash From Continuing Investing Activities
-1,046 -26,204 -6,044 733 -5,401 5,709 14,339 -4,024 -8,658 -5,547
Purchase of Property, Plant & Equipment
-1,096 -1,112 -936 -880 -608 -618 -738 -664 -738 -594
Acquisitions
0.00 -26,989 -3,839 -2,529 -3,219 -13,641 -40 -19 0.00 -359
Purchase of Investments
0.00 -1.00 -2,587 -8,900 -8,477 -9,394 -18,741 -33,607 -28,094 -25,977
Sale and/or Maturity of Investments
0.00 1,673 1,218 13,234 6,978 29,390 33,768 30,414 20,417 21,556
Other Investing Activities, net
50 225 100 -192 -75 -28 -105 -148 -243 -447
Net Cash From Financing Activities
-9,415 21,048 -4,037 -8,271 -4,867 -15,767 -22,490 -6,594 -2,599 -3,771
Net Cash From Continuing Financing Activities
-9,415 21,048 -4,037 -8,271 -4,867 -15,767 -22,490 -6,594 -2,599 -3,771
Repayment of Debt
-4,383 -2,173 -400 -4,228 -6,540 -4,556 -1,189 -4,405 - -2,319
Repurchase of Common Equity
-200 0.00 -6,360 -4,975 -3,486 -7,702 -17,794 -3,160 - -1,867
Payment of Dividends
-4,832 -4,556 -4,196 -4,013 -3,755 -3,509 -3,507 -3,365 - -2,396
Issuance of Debt
0.00 27,777 6,919 4,945 8,914 0.00 0.00 4,527 - 3,465

Quarterly Cash Flow Statements for Amgen

This table details how cash moves in and out of Amgen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-3,163 2,962 -290 -407 -1,236 -23,797 493 2,688 23,931 -1,873 4,299
Net Cash From Operating Activities
1,391 4,771 3,571 2,459 689 538 2,760 4,109 1,064 2,649 2,978
Net Cash From Continuing Operating Activities
1,391 4,771 3,571 2,459 689 538 2,760 4,109 1,064 2,649 2,978
Net Income / (Loss) Continuing Operations
1,730 627 2,830 746 -113 767 1,730 1,379 2,841 1,616 2,143
Consolidated Net Income / (Loss)
1,730 627 2,830 746 -113 767 1,730 1,379 2,841 1,616 2,143
Depreciation Expense
1,387 1,397 1,396 1,400 1,399 1,380 895 896 900 911 837
Non-Cash Adjustments To Reconcile Net Income
-460 1,002 -1,401 574 496 -88 529 873 -1,874 169 21
Changes in Operating Assets and Liabilities, net
-1,266 1,745 746 -261 -1,093 -1,521 -394 961 -803 -47 -23
Net Cash From Investing Activities
-447 -402 -210 -217 -217 -27,089 -262 -211 1,358 -3,473 -267
Net Cash From Continuing Investing Activities
-447 -402 -210 -217 -217 -27,089 -262 -211 1,358 -3,473 -267
Purchase of Property, Plant & Equipment
-411 -371 -257 -238 -230 -249 -248 -271 -344 -340 -160
Other Investing Activities, net
-36 -31 47 21 13 152 -14 59 28 159 -120
Net Cash From Financing Activities
-4,107 -1,407 -3,651 -2,649 -1,708 2,754 -2,005 -1,210 21,509 -1,049 1,588
Net Cash From Continuing Financing Activities
-4,107 -1,407 -3,651 -2,649 -1,708 2,754 -2,005 -1,210 21,509 -1,049 1,588
Repayment of Debt
-2,828 -2.00 -2,441 -1,440 -500 -102 -866 -53 -1,152 10 -358
Payment of Dividends
-1,279 -1,205 -1,210 -1,209 -1,208 -1,140 -1,140 -1,139 -1,137 -1,040 -1,038

Annual Balance Sheets for Amgen

This table presents Amgen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
91,839 97,154 65,121 61,165 62,948 59,707 66,416 79,954 77,626 71,449
Total Current Assets
29,030 30,332 22,186 19,385 21,144 18,440 37,618 49,476 46,010 38,515
Cash & Equivalents
11,973 10,944 7,629 7,989 6,266 6,037 6,945 3,800 3,241 4,144
Accounts Receivable
6,782 7,268 5,563 4,895 4,525 4,057 3,580 3,237 3,165 2,995
Inventories, net
6,998 9,518 4,930 4,086 3,893 3,584 2,940 2,834 2,745 2,435
Other Current Assets
3,277 2,602 2,388 2,367 2,079 1,888 1,794 1,727 2,015 1,703
Plant, Property, & Equipment, net
6,543 5,941 5,427 5,184 4,889 4,928 4,958 4,989 4,961 4,907
Total Noncurrent Assets
56,266 60,881 37,508 36,596 36,915 36,339 23,840 25,489 26,655 28,027
Goodwill
18,637 18,629 15,529 14,890 14,689 14,703 14,699 14,761 14,751 14,787
Intangible Assets
27,699 32,641 16,080 15,182 16,587 19,413 7,443 8,609 10,279 11,641
Other Noncurrent Operating Assets
9,930 9,611 5,899 6,524 5,639 2,223 1,698 2,119 1,625 1,599
Total Liabilities & Shareholders' Equity
91,839 97,154 65,121 61,165 62,948 59,707 66,416 79,954 77,626 71,449
Total Liabilities
85,962 90,922 61,460 54,465 53,539 50,034 53,916 54,713 47,751 43,366
Total Current Liabilities
23,099 18,392 15,687 12,184 11,653 12,835 13,488 9,020 11,204 8,664
Short-Term Debt
3,550 1,443 1,591 87 91 2,953 4,419 1,152 4,403 2,247
Accounts Payable
1,908 1,590 1,572 1,366 1,421 1,371 1,207 1,352 917 965
Accrued Expenses
17,641 15,359 12,524 10,731 10,141 8,511 7,862 6,516 5,884 5,452
Total Noncurrent Liabilities
62,863 72,530 45,773 42,281 41,886 37,199 40,428 45,693 36,547 34,702
Long-Term Debt
56,549 63,170 37,354 33,222 32,895 26,950 29,510 34,190 30,193 29,182
Noncurrent Deferred & Payable Income Tax Liabilities
3,965 7,034 5,768 6,594 6,968 8,037 9,634 10,265 4,855 4,212
Other Noncurrent Operating Liabilities
2,349 2,326 2,651 2,465 2,023 2,212 1,284 1,238 1,499 1,308
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
5,877 6,232 3,661 6,700 9,409 9,673 12,500 25,241 29,875 28,083
Total Preferred & Common Equity
5,877 6,232 3,661 6,700 9,409 9,673 12,500 25,241 29,875 28,083
Total Common Equity
5,877 6,232 3,661 6,700 9,409 9,673 12,500 25,241 29,875 28,083
Common Stock
33,533 33,070 32,514 32,096 31,802 31,531 31,246 30,992 30,784 30,649
Retained Earnings
-27,590 -26,549 -28,622 -24,600 -21,408 -21,330 -17,977 -5,072 -438 -2,086
Accumulated Other Comprehensive Income / (Loss)
-66 -289 -231 -796 -985 -528 -769 -679 -471 -480

Quarterly Balance Sheets for Amgen

This table presents Amgen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Total Assets
89,367 91,839 90,883 90,907 92,980 97,154 90,534 90,269 88,720 65,121 63,700
Total Current Assets
26,929 29,030 26,766 27,206 28,029 30,332 48,477 47,380 44,703 22,186 24,062
Cash & Equivalents
8,810 11,973 9,011 9,301 9,708 10,944 34,741 34,248 31,560 7,629 9,502
Accounts Receivable
8,132 6,782 7,317 6,934 6,776 7,268 6,145 5,830 5,736 5,563 5,326
Inventories, net
6,729 6,998 7,362 7,995 8,724 9,518 5,026 4,978 5,011 4,930 4,757
Other Current Assets
3,258 3,277 3,076 2,976 2,821 2,602 2,565 2,324 2,395 2,388 2,501
Plant, Property, & Equipment, net
6,681 6,543 6,156 6,097 6,002 5,941 5,563 5,532 5,460 5,427 5,188
Total Noncurrent Assets
55,757 56,266 57,961 57,604 58,949 60,881 36,494 37,357 38,557 37,508 34,450
Goodwill
18,645 18,637 18,658 18,616 18,570 18,629 15,509 15,531 15,531 15,529 14,845
Intangible Assets
25,724 27,699 28,920 30,172 31,372 32,641 13,150 14,633 15,393 16,080 13,266
Other Noncurrent Operating Assets
11,388 9,930 10,383 8,816 9,007 9,611 7,835 7,193 7,633 5,899 6,339
Total Liabilities & Shareholders' Equity
89,367 91,839 90,883 90,907 92,980 97,154 90,534 90,269 88,720 65,121 63,700
Total Liabilities
83,160 85,962 83,356 84,982 87,958 90,922 82,878 83,488 83,372 61,460 60,047
Total Current Liabilities
23,008 23,099 20,312 21,517 19,714 18,392 16,954 17,097 14,215 15,687 14,331
Short-Term Debt
3,368 3,550 3,544 5,528 3,959 1,443 1,428 2,167 834 1,591 1,543
Accounts Payable
2,406 1,908 2,147 2,267 1,628 1,590 1,358 1,212 1,320 1,572 1,204
Accrued Expenses
17,234 17,641 14,621 13,722 14,127 15,359 14,168 13,718 12,061 12,524 11,584
Total Noncurrent Liabilities
60,152 62,863 63,044 63,465 68,244 72,530 65,924 66,391 69,157 45,773 45,716
Long-Term Debt
54,013 56,549 56,854 57,117 60,061 63,170 59,040 59,377 60,761 37,354 37,161
Noncurrent Deferred & Payable Income Tax Liabilities
3,929 3,965 3,991 3,985 5,826 7,034 4,579 4,478 5,864 5,768 5,680
Other Noncurrent Operating Liabilities
2,210 2,349 2,199 2,363 2,357 2,326 2,305 2,536 2,532 2,651 2,875
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
6,207 5,877 7,527 5,925 5,022 6,232 7,656 6,781 5,348 3,661 3,653
Total Preferred & Common Equity
6,207 5,877 7,527 5,925 5,022 6,232 7,656 6,781 5,348 3,661 3,653
Total Common Equity
6,207 5,877 7,527 5,925 5,022 6,232 7,656 6,781 5,348 3,661 3,653
Common Stock
33,578 33,533 33,393 33,204 33,082 33,070 32,753 32,601 32,535 32,514 32,371
Retained Earnings
-27,140 -27,590 -25,530 -27,124 -27,870 -26,549 -24,971 -25,540 -26,919 -28,622 -28,066
Accumulated Other Comprehensive Income / (Loss)
-231 -66 -336 -155 -190 -289 -126 -280 -268 -231 -652

Annual Metrics And Ratios for Amgen

This table displays calculated financial ratios and metrics derived from Amgen's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
18.57% 7.09% 1.32% 2.18% 8.83% -1.62% 3.93% -0.62% 6.14% 7.97%
EBITDA Growth
-9.76% 21.63% 7.73% -13.08% 2.87% -1.94% 0.21% 2.62% 12.05% 27.81%
EBIT Growth
-27.64% 22.60% 10.81% -15.93% -9.90% -4.66% 0.33% 4.59% 14.88% 36.31%
NOPAT Growth
-4.62% -20.85% 27.00% -17.70% -1.68% -8.02% 338.87% -75.08% 12.04% 28.84%
Net Income Growth
-39.11% 2.52% 11.18% -18.87% -7.37% -6.58% 324.15% -74.37% 11.28% 34.53%
EPS Growth
-39.47% 3.14% 17.80% -16.49% -4.43% 2.06% 369.15% -73.73% 13.02% 35.22%
Operating Cash Flow Growth
35.64% -12.86% 4.97% -11.77% 14.72% -19.00% 1.06% 7.95% 6.40% 8.70%
Free Cash Flow Firm Growth
162.17% -375.54% 10.92% -8.27% 235.16% -148.48% 13.29% -4.60% 14.87% 13.60%
Invested Capital Growth
-9.85% 79.88% 4.16% 0.71% 3.53% 79.07% -9.42% -28.35% -6.20% -4.54%
Revenue Q/Q Growth
2.74% 5.06% -0.03% 0.82% 1.75% -0.14% 1.84% -0.71% 1.90% 0.96%
EBITDA Q/Q Growth
-0.94% -0.14% -1.97% 2.26% 0.64% -0.32% 0.25% -1.34% 3.56% 6.34%
EBIT Q/Q Growth
-1.82% -4.37% -3.35% 3.55% -0.94% -2.37% -0.08% -0.59% 4.14% 7.72%
NOPAT Q/Q Growth
14.58% -11.80% 0.08% 5.16% -0.35% -3.96% 287.53% -76.20% 2.40% 6.61%
Net Income Q/Q Growth
-3.31% -11.22% -4.14% 5.06% -1.20% -2.79% 281.20% -75.80% 1.78% 7.87%
EPS Q/Q Growth
-3.20% -11.23% -2.65% 5.87% -0.81% -1.30% 230.37% -75.66% 2.30% 8.11%
Operating Cash Flow Q/Q Growth
58.33% -19.95% -1.61% 7.61% -3.32% -6.92% 1.64% -0.78% 11.01% -7.32%
Free Cash Flow Firm Q/Q Growth
161.97% -485.17% -31.54% 1.47% 246.57% -168.61% 6.69% -5.60% 16.90% 2.02%
Invested Capital Q/Q Growth
-8.34% 79.44% 7.84% -2.75% -3.46% 54.37% -9.18% -29.07% -6.15% -1.67%
Profitability Metrics
- - - - - - - - - -
Gross Margin
61.53% 70.02% 75.66% 75.16% 75.77% 81.35% 82.73% 82.19% 81.90% 80.49%
EBITDA Margin
39.96% 52.50% 46.23% 43.48% 51.12% 54.08% 54.25% 56.27% 54.49% 51.62%
Operating Margin
21.71% 28.01% 36.34% 29.40% 35.95% 41.41% 43.22% 43.65% 42.60% 39.10%
EBIT Margin
23.23% 38.06% 33.25% 30.40% 36.95% 44.63% 46.06% 47.71% 45.34% 41.88%
Profit (Net Income) Margin
12.24% 23.83% 24.89% 22.68% 28.57% 33.57% 35.35% 8.66% 33.59% 32.03%
Tax Burden Percent
88.74% 85.51% 89.19% 87.94% 89.32% 85.82% 87.94% 20.62% 84.27% 86.98%
Interest Burden Percent
59.36% 73.21% 83.94% 84.84% 86.57% 87.64% 87.27% 88.04% 87.91% 87.93%
Effective Tax Rate
11.26% 14.49% 10.81% 12.06% 10.68% 14.18% 12.06% 79.38% 15.73% 13.02%
Return on Invested Capital (ROIC)
11.31% 14.49% 26.14% 21.09% 26.16% 34.74% 50.10% 9.08% 30.28% 25.58%
ROIC Less NNEP Spread (ROIC-NNEP)
6.69% 14.40% 18.93% 17.62% 22.01% 31.15% 123.91% 10.66% 61.18% 2.67%
Return on Net Nonoperating Assets (RNNOA)
56.24% 121.30% 100.33% 52.08% 49.98% 35.99% -5.62% -1.90% -3.63% 0.19%
Return on Equity (ROE)
67.55% 135.79% 126.47% 73.16% 76.13% 70.73% 44.48% 7.18% 26.65% 25.77%
Cash Return on Invested Capital (CROIC)
21.67% -42.59% 22.07% 20.38% 22.69% -21.92% 59.98% 42.12% 36.68% 30.22%
Operating Return on Assets (OROA)
8.22% 13.22% 13.86% 12.73% 15.32% 16.53% 14.94% 13.84% 13.98% 12.92%
Return on Assets (ROA)
4.33% 8.28% 10.38% 9.50% 11.84% 12.44% 11.47% 2.51% 10.36% 9.88%
Return on Common Equity (ROCE)
67.55% 135.79% 126.47% 73.16% 76.13% 70.73% 44.48% 7.18% 26.65% 25.77%
Return on Equity Simple (ROE_SIMPLE)
69.59% 107.78% 178.97% 87.96% 77.20% 81.07% 67.15% 7.84% 25.85% 24.71%
Net Operating Profit after Tax (NOPAT)
6,441 6,753 8,532 6,718 8,163 8,302 9,025 2,057 8,254 7,367
NOPAT Margin
19.27% 23.96% 32.41% 25.86% 32.11% 35.54% 38.01% 9.00% 35.90% 34.01%
Net Nonoperating Expense Percent (NNEP)
4.62% 0.09% 7.21% 3.47% 4.15% 3.59% -73.81% -1.58% -30.90% 22.91%
Return On Investment Capital (ROIC_SIMPLE)
9.76% 9.53% 20.03% - - - - - - -
Cost of Revenue to Revenue
38.47% 29.98% 24.34% 24.84% 24.23% 18.65% 17.27% 17.81% 18.10% 19.51%
SG&A Expenses to Revenue
21.97% 25.04% 22.48% 21.41% 23.28% 22.33% 23.78% 22.96% 22.60% 22.60%
R&D to Revenue
17.84% 16.97% 16.84% 24.34% 16.55% 17.62% 15.74% 15.59% 16.70% 18.79%
Operating Expenses to Revenue
39.82% 42.01% 39.32% 45.75% 39.83% 39.95% 39.51% 38.54% 39.30% 41.39%
Earnings before Interest and Taxes (EBIT)
7,764 10,730 8,752 7,898 9,395 10,427 10,937 10,901 10,423 9,073
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
13,356 14,801 12,169 11,296 12,996 12,633 12,883 12,856 12,528 11,181
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
23.65 23.82 35.62 17.34 12.55 12.72 8.27 4.05 2.87 3.35
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 54.63 17.68 56.78
Price to Revenue (P/Rev)
4.16 5.27 4.95 4.47 4.65 5.27 4.35 4.47 3.73 4.34
Price to Earnings (P/E)
33.98 22.10 19.91 19.71 16.26 15.69 12.32 51.65 11.09 13.54
Dividend Yield
3.48% 3.07% 3.17% 4.27% 3.15% 2.80% 3.25% 3.27% 3.47% 2.54%
Earnings Yield
2.94% 4.53% 5.02% 5.07% 6.15% 6.37% 8.12% 1.94% 9.01% 7.38%
Enterprise Value to Invested Capital (EV/IC)
3.46 3.37 4.81 4.42 4.42 4.70 6.31 5.07 3.11 3.34
Enterprise Value to Revenue (EV/Rev)
5.60 7.17 6.08 5.44 5.53 6.16 4.55 4.20 3.57 4.34
Enterprise Value to EBITDA (EV/EBITDA)
14.01 13.65 13.15 12.52 10.81 11.40 8.38 7.46 6.56 8.41
Enterprise Value to EBIT (EV/EBIT)
24.10 18.83 18.29 17.91 14.95 13.81 9.88 8.79 7.88 10.36
Enterprise Value to NOPAT (EV/NOPAT)
29.05 29.93 18.76 21.05 17.21 17.35 11.97 46.62 9.96 12.76
Enterprise Value to Operating Cash Flow (EV/OCF)
16.28 23.86 16.47 15.27 13.38 15.74 9.56 8.58 7.94 9.66
Enterprise Value to Free Cash Flow (EV/FCFF)
15.16 0.00 22.22 21.78 19.84 0.00 10.00 10.05 8.22 10.80
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
10.23 10.37 10.64 4.97 3.51 3.09 2.71 1.40 1.16 1.12
Long-Term Debt to Equity
9.62 10.14 10.20 4.96 3.50 2.79 2.36 1.35 1.01 1.04
Financial Leverage
8.41 8.42 5.30 2.96 2.27 1.16 -0.05 -0.18 -0.06 0.07
Leverage Ratio
15.61 16.40 12.19 7.70 6.43 5.69 3.88 2.86 2.57 2.61
Compound Leverage Factor
9.27 12.01 10.23 6.54 5.56 4.99 3.38 2.52 2.26 2.29
Debt to Total Capital
91.09% 91.20% 91.41% 83.25% 77.81% 75.56% 73.08% 58.34% 53.66% 52.81%
Short-Term Debt to Total Capital
5.38% 2.04% 3.73% 0.22% 0.21% 7.46% 9.52% 1.90% 6.83% 3.78%
Long-Term Debt to Total Capital
85.71% 89.17% 87.67% 83.04% 77.59% 68.10% 63.56% 56.44% 46.83% 49.04%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
8.91% 8.80% 8.59% 16.75% 22.19% 24.44% 26.92% 41.66% 46.34% 47.19%
Debt to EBITDA
4.50 4.37 3.20 2.95 2.54 2.37 2.63 2.75 2.76 2.81
Net Debt to EBITDA
3.60 3.63 2.44 2.24 1.72 1.66 0.36 -0.49 -0.28 0.00
Long-Term Debt to EBITDA
4.23 4.27 3.07 2.94 2.53 2.13 2.29 2.66 2.41 2.61
Debt to NOPAT
9.33 9.57 4.56 4.96 4.04 3.60 3.76 17.19 4.19 4.27
Net Debt to NOPAT
7.47 7.95 3.47 3.76 2.74 2.53 0.51 -3.08 -0.42 0.01
Long-Term Debt to NOPAT
8.78 9.35 4.38 4.95 4.03 3.25 3.27 16.63 3.66 3.96
Altman Z-Score
1.27 1.40 1.63 1.71 1.93 2.06 2.11 2.37 2.35 2.48
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.26 1.65 1.41 1.59 1.81 1.44 2.79 5.49 4.11 4.45
Quick Ratio
0.81 0.99 0.95 1.06 1.30 1.01 2.44 4.98 3.68 3.97
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
12,339 -19,847 7,203 6,494 7,080 -5,238 10,805 9,538 9,998 8,704
Operating Cash Flow to CapEx
1,048.36% 761.78% 1,038.57% 1,052.39% 1,726.48% 1,480.58% 1,530.62% 1,683.28% 1,402.98% 3,040.94%
Free Cash Flow to Firm to Interest Expense
3.91 -6.90 5.12 5.43 5.61 -4.06 7.76 7.31 7.93 7.95
Operating Cash Flow to Interest Expense
3.64 2.95 6.91 7.74 8.32 7.10 8.11 8.57 8.22 8.89
Operating Cash Flow Less CapEx to Interest Expense
3.29 2.56 6.25 7.00 7.84 6.62 7.58 8.06 7.63 8.59
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.35 0.35 0.42 0.42 0.41 0.37 0.32 0.29 0.31 0.31
Accounts Receivable Turnover
4.76 4.39 5.03 5.52 5.93 6.12 6.97 7.14 7.46 7.82
Inventory Turnover
1.56 1.17 1.42 1.62 1.65 1.34 1.42 1.46 1.61 1.66
Fixed Asset Turnover
5.35 4.96 4.96 5.16 5.18 4.73 4.77 4.59 4.66 4.28
Accounts Payable Turnover
7.35 5.35 4.36 4.63 4.41 3.38 3.21 3.59 4.42 4.31
Days Sales Outstanding (DSO)
76.72 83.07 72.51 66.17 61.60 59.66 52.39 51.13 48.90 46.68
Days Inventory Outstanding (DIO)
234.42 312.01 256.86 225.62 221.55 273.33 256.95 250.23 227.14 219.41
Days Payable Outstanding (DPO)
49.65 68.28 83.70 78.81 82.73 108.01 113.88 101.77 82.52 84.62
Cash Conversion Cycle (CCC)
261.49 326.79 245.66 212.99 200.43 224.98 195.46 199.59 193.51 181.47
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
54,003 59,901 33,301 31,972 31,748 30,665 17,125 18,905 26,386 28,130
Invested Capital Turnover
0.59 0.60 0.81 0.82 0.81 0.98 1.32 1.01 0.84 0.75
Increase / (Decrease) in Invested Capital
-5,898 26,600 1,329 224 1,083 13,540 -1,780 -7,481 -1,744 -1,337
Enterprise Value (EV)
187,106 202,091 160,059 141,435 140,468 144,006 108,013 95,872 82,179 94,013
Market Capitalization
138,980 148,422 130,419 116,163 118,129 123,014 103,388 102,208 85,668 93,966
Book Value per Share
$10.93 $11.64 $6.86 $11.89 $16.16 $16.28 $19.62 $34.77 $40.16 $37.23
Tangible Book Value per Share
($75.27) ($84.16) ($52.38) ($41.49) ($37.56) ($41.14) ($15.13) $2.58 $6.51 $2.19
Total Capital
65,976 70,845 42,606 40,009 42,395 39,576 46,429 60,583 64,471 59,512
Total Debt
60,099 64,613 38,945 33,309 32,986 29,903 33,929 35,342 34,596 31,429
Total Long-Term Debt
56,549 63,170 37,354 33,222 32,895 26,950 29,510 34,190 30,193 29,182
Net Debt
48,126 53,669 29,640 25,272 22,339 20,992 4,625 -6,336 -3,489 47
Capital Expenditures (CapEx)
1,096 1,112 936 880 608 618 738 664 738 320
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2,492 2,439 -1,215 -749 -1,065 -353 -755 -70 1,124 716
Debt-free Net Working Capital (DFNWC)
9,481 13,383 8,090 7,288 9,582 8,558 28,549 41,608 39,209 32,098
Net Working Capital (NWC)
5,931 11,940 6,499 7,201 9,491 5,605 24,130 40,456 34,806 29,851
Net Nonoperating Expense (NNE)
2,351 36 1,980 825 899 460 631 78 532 428
Net Nonoperating Obligations (NNO)
48,126 53,669 29,640 25,272 22,339 20,992 4,625 -6,336 -3,489 47
Total Depreciation and Amortization (D&A)
5,592 4,071 3,417 3,398 3,601 2,206 1,946 1,955 2,105 2,108
Debt-free, Cash-free Net Working Capital to Revenue
-7.46% 8.65% -4.62% -2.88% -4.19% -1.51% -3.18% -0.31% 4.89% 3.31%
Debt-free Net Working Capital to Revenue
28.37% 47.47% 30.73% 28.05% 37.69% 36.63% 120.22% 182.10% 170.54% 148.18%
Net Working Capital to Revenue
17.74% 42.36% 24.69% 27.72% 37.33% 23.99% 101.61% 177.06% 151.39% 137.80%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$7.62 $12.56 $12.18 $10.34 $12.40 $12.96 $12.70 $2.71 $10.32 $9.15
Adjusted Weighted Average Basic Shares Outstanding
537M 535M 538M 570M 586M 605M 661M 731M 748M 758M
Adjusted Diluted Earnings per Share
$7.56 $12.49 $12.11 $10.28 $12.31 $12.88 $12.62 $2.69 $10.24 $9.06
Adjusted Weighted Average Diluted Shares Outstanding
541M 538M 541M 573M 590M 609M 665M 735M 754M 766M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
537.20M 535.92M 533.98M 557.03M 577.57M 589.81M 622.28M 720.56M 736.45M 752.09M
Normalized Net Operating Profit after Tax (NOPAT)
6,441 6,753 8,532 6,718 8,163 8,302 9,025 6,981 8,254 7,367
Normalized NOPAT Margin
19.27% 23.96% 32.41% 25.86% 32.11% 35.54% 38.01% 30.55% 35.90% 34.01%
Pre Tax Income Margin
13.79% 27.86% 27.91% 25.79% 31.99% 39.11% 40.19% 42.00% 39.85% 36.83%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
2.46 3.73 6.22 6.60 7.44 8.09 7.86 8.36 8.27 8.29
NOPAT to Interest Expense
2.04 2.35 6.07 5.61 6.47 6.44 6.48 1.58 6.55 6.73
EBIT Less CapEx to Interest Expense
2.11 3.35 5.56 5.86 6.96 7.61 7.33 7.85 7.69 7.99
NOPAT Less CapEx to Interest Expense
1.69 1.96 5.40 4.88 5.99 5.96 5.95 1.07 5.96 6.44
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
118.14% 67.83% 64.04% 68.10% 51.69% 44.75% 41.78% 170.04% 0.00% 34.53%
Augmented Payout Ratio
123.03% 67.83% 161.11% 152.52% 99.68% 142.96% 253.76% 329.71% 0.00% 61.44%

Quarterly Metrics And Ratios for Amgen

This table displays calculated financial ratios and metrics derived from Amgen's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
9.43% 10.86% 23.18% 20.07% 21.98% 19.84% 3.77% 5.94% -2.13% -0.10% -0.81%
EBITDA Growth
89.47% -4.16% 46.43% -7.97% -55.89% -0.68% 0.11% 21.40% 73.78% -7.35% 8.97%
EBIT Growth
256.61% -8.61% 43.27% -32.29% -81.03% -22.65% -1.96% 27.27% 102.28% -12.29% 12.61%
NOPAT Growth
48.90% 61.94% 4.03% -21.79% -56.25% -44.50% -24.65% 22.51% -28.03% 0.41% 14.63%
Net Income Growth
1,630.97% -18.25% 63.58% -45.90% -103.98% -52.54% -19.27% 4.71% 92.48% -14.90% 13.75%
EPS Growth
1,623.81% -17.61% 62.11% -46.30% -103.98% -52.67% -19.10% 4.90% 97.01% -9.91% 20.24%
Operating Cash Flow Growth
101.89% 786.80% 29.38% -40.16% -35.24% -79.69% -7.32% 112.90% -50.83% -5.66% 23.16%
Free Cash Flow Firm Growth
124.03% 130.45% -3,241.05% -90,615.89% -804.84% -3,574.71% -116.17% -100.84% -205.78% -59.95% 109.53%
Invested Capital Growth
-7.68% -9.85% 76.48% 73.93% 67.70% 79.88% 8.11% 7.30% 13.31% 4.16% -6.07%
Revenue Q/Q Growth
-10.31% 6.86% 1.37% 12.64% -9.14% 18.73% -1.19% 14.43% -10.73% 2.81% 0.88%
EBITDA Q/Q Growth
39.54% -44.51% 75.65% 39.30% -29.41% -15.22% 10.39% -33.22% 58.91% -14.54% 33.87%
EBIT Q/Q Growth
76.32% -60.56% 142.01% 111.90% -54.81% -38.17% 14.37% -40.63% 84.23% -21.63% 48.47%
NOPAT Q/Q Growth
-44.26% -0.81% 4.15% 158.55% -39.37% -36.28% -21.69% 44.63% -23.09% -13.49% 27.31%
Net Income Q/Q Growth
175.92% -77.84% 279.36% 760.18% -114.73% -55.66% 25.45% -51.46% 75.80% -24.59% 62.72%
EPS Q/Q Growth
173.50% -77.59% 278.26% 757.14% -114.79% -55.90% 25.29% -51.33% 76.00% -24.62% 62.45%
Operating Cash Flow Q/Q Growth
-70.84% 33.60% 45.22% 256.89% 28.07% -80.51% -32.83% 286.18% -59.83% -11.05% 54.30%
Free Cash Flow Firm Q/Q Growth
-27.89% 132.76% -1.13% -0.60% 8.63% -3,494.20% -2,645.88% 99.00% -450.86% -83.27% 43.07%
Invested Capital Q/Q Growth
1.44% -8.34% -0.60% -0.11% -0.95% 79.44% -2.04% -3.69% 6.25% 7.84% -2.77%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
63.58% 65.75% 61.07% 61.42% 57.03% 62.03% 73.84% 74.05% 71.83% 74.46% 76.13%
EBITDA Margin
50.10% 32.20% 62.01% 35.79% 28.94% 37.25% 52.17% 46.69% 80.02% 44.95% 54.07%
Operating Margin
14.46% 25.43% 24.07% 22.76% 13.31% 15.51% 29.28% 38.42% 31.47% 32.61% 39.99%
EBIT Margin
33.08% 16.83% 45.60% 19.10% 10.15% 20.41% 39.20% 33.87% 65.27% 31.63% 41.49%
Profit (Net Income) Margin
21.23% 6.90% 33.28% 8.89% -1.52% 9.36% 25.06% 19.74% 46.54% 23.63% 32.22%
Tax Burden Percent
87.68% 80.18% 91.26% 93.95% 166.18% 90.02% 88.85% 85.44% 82.54% 92.45% 89.59%
Interest Burden Percent
73.18% 51.14% 79.98% 49.56% -8.99% 50.93% 71.95% 68.22% 86.37% 80.81% 86.67%
Effective Tax Rate
12.32% 19.82% 8.74% 6.05% 0.00% 9.98% 11.15% 14.56% 17.46% 7.55% 10.41%
Return on Invested Capital (ROIC)
7.58% 11.97% 15.49% 14.17% 5.81% 8.45% 21.72% 26.51% 20.42% 24.31% 29.59%
ROIC Less NNEP Spread (ROIC-NNEP)
8.94% 9.56% 17.98% 11.57% 3.90% 7.54% 21.48% 23.28% 24.58% 22.69% 28.67%
Return on Net Nonoperating Assets (RNNOA)
81.88% 80.37% 91.34% 73.46% 31.69% 63.49% 100.56% 143.31% 236.84% 120.26% 125.30%
Return on Equity (ROE)
89.46% 92.33% 106.82% 87.63% 37.50% 71.93% 122.29% 169.82% 257.26% 144.57% 154.89%
Cash Return on Invested Capital (CROIC)
19.63% 21.67% -43.14% -42.20% -37.84% -42.59% 16.04% 17.98% 10.96% 22.07% 33.00%
Operating Return on Assets (OROA)
12.38% 5.95% 16.35% 6.52% 3.30% 7.09% 13.64% 12.04% 23.12% 13.18% 16.98%
Return on Assets (ROA)
7.95% 2.44% 11.94% 3.04% -0.49% 3.25% 8.72% 7.02% 16.48% 9.85% 13.18%
Return on Common Equity (ROCE)
89.46% 92.33% 106.82% 87.63% 37.50% 71.93% 122.29% 169.82% 257.26% 144.57% 154.89%
Return on Equity Simple (ROE_SIMPLE)
95.59% 0.00% 56.20% 52.83% 74.93% 0.00% 98.82% 117.67% 148.04% 0.00% 187.11%
Net Operating Profit after Tax (NOPAT)
1,033 1,853 1,868 1,794 694 1,144 1,796 2,293 1,586 2,062 2,383
NOPAT Margin
12.68% 20.39% 21.97% 21.38% 9.32% 13.96% 26.01% 32.83% 25.97% 30.14% 35.83%
Net Nonoperating Expense Percent (NNEP)
-1.36% 2.41% -2.49% 2.60% 1.91% 0.91% 0.25% 3.23% -4.16% 1.62% 0.93%
Return On Investment Capital (ROIC_SIMPLE)
1.62% 2.81% - - - 1.62% - - - 4.84% -
Cost of Revenue to Revenue
36.42% 34.25% 38.93% 38.58% 42.97% 37.97% 26.16% 25.95% 28.17% 25.54% 23.87%
SG&A Expenses to Revenue
30.89% 23.40% 19.11% 21.28% 24.28% 38.47% 19.60% 18.52% 20.61% 30.34% 19.35%
R&D to Revenue
18.24% 18.97% 17.05% 17.25% 18.03% 18.72% 15.63% 15.93% 17.33% 19.36% 16.72%
Operating Expenses to Revenue
49.12% 40.31% 37.00% 38.66% 43.72% 46.52% 44.56% 35.63% 40.36% 41.85% 36.14%
Earnings before Interest and Taxes (EBIT)
2,696 1,529 3,877 1,602 756 1,673 2,706 2,366 3,985 2,163 2,760
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4,083 2,926 5,273 3,002 2,155 3,053 3,601 3,262 4,885 3,074 3,597
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
26.96 23.65 23.00 28.09 29.88 23.82 18.23 16.85 23.03 35.62 31.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
4.90 4.16 5.32 5.38 5.08 5.27 5.20 4.30 4.70 4.95 4.30
Price to Earnings (P/E)
28.21 33.98 40.93 53.18 39.87 22.10 18.45 14.32 15.56 19.91 16.57
Dividend Yield
2.93% 3.48% 2.76% 2.82% 3.08% 3.07% 3.19% 3.81% 3.45% 3.17% 3.58%
Earnings Yield
3.54% 2.94% 2.44% 1.88% 2.51% 4.53% 5.42% 6.98% 6.43% 5.02% 6.04%
Enterprise Value to Invested Capital (EV/IC)
3.94 3.46 3.81 3.71 3.44 3.37 4.95 4.15 4.33 4.81 4.55
Enterprise Value to Revenue (EV/Rev)
6.33 5.60 6.90 7.11 6.92 7.17 6.16 5.32 5.85 6.08 5.33
Enterprise Value to EBITDA (EV/EBITDA)
14.13 14.01 16.65 18.61 16.93 13.65 11.15 9.55 10.76 13.15 11.32
Enterprise Value to EBIT (EV/EBIT)
22.25 24.10 28.39 32.62 27.24 18.83 14.73 12.55 14.23 18.29 15.51
Enterprise Value to NOPAT (EV/NOPAT)
32.51 29.05 39.94 39.98 33.87 29.93 21.59 17.18 19.62 18.76 16.48
Enterprise Value to Operating Cash Flow (EV/OCF)
17.71 16.28 30.94 34.10 25.24 23.86 15.62 13.11 17.77 16.47 14.22
Enterprise Value to Free Cash Flow (EV/FCFF)
19.28 15.16 0.00 0.00 0.00 0.00 32.08 23.91 41.95 22.22 13.35
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
9.24 10.23 8.02 10.57 12.75 10.37 7.90 9.08 11.52 10.64 10.60
Long-Term Debt to Equity
8.70 9.62 7.55 9.64 11.96 10.14 7.71 8.76 11.36 10.20 10.17
Financial Leverage
9.16 8.41 5.08 6.35 8.13 8.42 4.68 6.16 9.63 5.30 4.37
Leverage Ratio
16.24 15.61 11.95 14.26 17.52 16.40 13.64 16.26 23.61 12.19 10.84
Compound Leverage Factor
11.88 7.98 9.56 7.07 -1.58 8.35 9.81 11.09 20.40 9.85 9.40
Debt to Total Capital
90.24% 91.09% 88.92% 91.36% 92.73% 91.20% 88.76% 90.08% 92.01% 91.41% 91.38%
Short-Term Debt to Total Capital
5.30% 5.38% 5.22% 8.06% 5.73% 2.04% 2.10% 3.17% 1.25% 3.73% 3.64%
Long-Term Debt to Total Capital
84.94% 85.71% 83.70% 83.30% 86.99% 89.17% 86.67% 86.90% 90.77% 87.67% 87.73%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
9.76% 8.91% 11.08% 8.64% 7.27% 8.80% 11.24% 9.92% 7.99% 8.59% 8.62%
Debt to EBITDA
3.75 4.50 4.48 5.30 5.30 4.37 4.08 4.15 4.32 3.20 3.12
Net Debt to EBITDA
3.18 3.60 3.81 4.52 4.50 3.63 1.74 1.84 2.11 2.44 2.19
Long-Term Debt to EBITDA
3.53 4.23 4.22 4.84 4.98 4.27 3.98 4.01 4.27 3.07 2.99
Debt to NOPAT
8.64 9.33 10.74 11.39 10.61 9.57 7.90 7.47 7.89 4.56 4.54
Net Debt to NOPAT
7.31 7.47 9.14 9.70 9.00 7.95 3.36 3.31 3.85 3.47 3.19
Long-Term Debt to NOPAT
8.13 8.78 10.11 10.39 9.95 9.35 7.71 7.21 7.78 4.38 4.36
Altman Z-Score
1.32 1.05 1.44 1.23 1.06 1.09 1.44 1.21 1.32 1.29 1.25
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.17 1.26 1.32 1.26 1.42 1.65 2.86 2.77 3.14 1.41 1.68
Quick Ratio
0.74 0.81 0.80 0.75 0.84 0.99 2.41 2.34 2.62 0.95 1.17
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
5,589 7,751 -23,663 -23,398 -23,258 -25,456 -708 -26 -2,570 733 4,379
Operating Cash Flow to CapEx
338.44% 1,285.98% 1,389.49% 1,033.19% 299.57% 216.06% 1,112.90% 1,516.24% 309.30% 779.12% 1,861.25%
Free Cash Flow to Firm to Interest Expense
7.73 10.38 -30.49 -28.96 -28.23 -31.01 -0.93 -0.03 -4.73 1.77 11.90
Operating Cash Flow to Interest Expense
1.92 6.39 4.60 3.04 0.84 0.66 3.64 5.46 1.96 6.38 8.09
Operating Cash Flow Less CapEx to Interest Expense
1.36 5.89 4.27 2.75 0.56 0.35 3.31 5.10 1.33 5.56 7.66
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.37 0.35 0.36 0.34 0.33 0.35 0.35 0.36 0.35 0.42 0.41
Accounts Receivable Turnover
4.58 4.76 4.83 4.85 4.72 4.39 4.68 4.77 4.84 5.03 5.22
Inventory Turnover
1.63 1.56 2.08 1.75 1.45 1.17 1.45 1.44 1.39 1.42 1.43
Fixed Asset Turnover
5.38 5.35 5.55 5.32 5.15 4.96 4.99 4.97 4.94 4.96 5.18
Accounts Payable Turnover
6.26 7.35 7.34 6.53 6.74 5.35 5.53 5.57 4.82 4.36 5.37
Days Sales Outstanding (DSO)
79.73 76.72 75.52 75.30 77.32 83.07 78.02 76.60 75.35 72.51 69.94
Days Inventory Outstanding (DIO)
223.36 234.42 175.83 208.52 252.41 312.01 251.96 253.29 261.92 256.86 254.96
Days Payable Outstanding (DPO)
58.31 49.65 49.75 55.92 54.17 68.28 65.98 65.58 75.70 83.70 67.97
Cash Conversion Cycle (CCC)
244.78 261.49 201.60 227.91 275.55 326.79 263.99 264.31 261.57 245.66 256.94
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
54,778 54,003 58,914 59,269 59,334 59,901 33,383 34,077 35,382 33,301 30,879
Invested Capital Turnover
0.60 0.59 0.71 0.66 0.62 0.60 0.84 0.81 0.79 0.81 0.83
Increase / (Decrease) in Invested Capital
-4,556 -5,898 25,531 25,192 23,952 26,600 2,504 2,319 4,156 1,329 -1,996
Enterprise Value (EV)
215,937 187,106 224,520 219,794 204,356 202,091 165,289 141,538 153,184 160,059 140,467
Market Capitalization
167,366 138,980 173,133 166,450 150,044 148,422 139,562 114,242 123,150 130,419 113,241
Book Value per Share
$11.55 $10.93 $14.01 $11.05 $9.37 $11.64 $14.31 $12.69 $10.02 $6.86 $6.83
Tangible Book Value per Share
($71.04) ($75.27) ($74.54) ($79.90) ($83.81) ($84.16) ($39.27) ($43.76) ($47.90) ($52.38) ($45.72)
Total Capital
63,588 65,976 67,925 68,570 69,042 70,845 68,124 68,325 66,943 42,606 42,357
Total Debt
57,381 60,099 60,398 62,645 64,020 64,613 60,468 61,544 61,595 38,945 38,704
Total Long-Term Debt
54,013 56,549 56,854 57,117 60,061 63,170 59,040 59,377 60,761 37,354 37,161
Net Debt
48,571 48,126 51,387 53,344 54,312 53,669 25,727 27,296 30,034 29,640 27,226
Capital Expenditures (CapEx)
411 371 257 238 230 249 248 271 344 340 160
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1,521 -2,492 987 1,916 2,566 2,439 -1,790 -1,798 -239 -1,215 -204
Debt-free Net Working Capital (DFNWC)
7,289 9,481 9,998 11,217 12,274 13,383 32,951 32,450 31,322 8,090 11,274
Net Working Capital (NWC)
3,921 5,931 6,454 5,689 8,315 11,940 31,523 30,283 30,488 6,499 9,731
Net Nonoperating Expense (NNE)
-697 1,226 -962 1,048 807 377 66 914 -1,255 446 240
Net Nonoperating Obligations (NNO)
48,571 48,126 51,387 53,344 54,312 53,669 25,727 27,296 30,034 29,640 27,226
Total Depreciation and Amortization (D&A)
1,387 1,397 1,396 1,400 1,399 1,380 895 896 900 911 837
Debt-free, Cash-free Net Working Capital to Revenue
-4.46% -7.46% 3.03% 6.19% 8.69% 8.65% -6.67% -6.76% -0.91% -4.62% -0.77%
Debt-free Net Working Capital to Revenue
21.36% 28.37% 30.73% 36.26% 41.56% 47.47% 122.80% 122.08% 119.60% 30.73% 42.82%
Net Working Capital to Revenue
11.49% 17.74% 19.84% 18.39% 28.16% 42.36% 117.48% 113.92% 116.41% 24.69% 36.96%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$3.22 $1.17 $5.27 $1.39 ($0.21) $1.43 $3.23 $2.58 $5.32 $3.02 $4.01
Adjusted Weighted Average Basic Shares Outstanding
538M 537M 537M 537M 536M 535M 535M 535M 534M 538M 535M
Adjusted Diluted Earnings per Share
$3.20 $1.17 $5.22 $1.38 ($0.21) $1.42 $3.22 $2.57 $5.28 $3.00 $3.98
Adjusted Weighted Average Diluted Shares Outstanding
541M 541M 542M 541M 536M 538M 538M 537M 538M 541M 538M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
537.71M 537.20M 537.53M 537.33M 536.43M 535.92M 535.18M 534.90M 534.33M 533.98M 533.58M
Normalized Net Operating Profit after Tax (NOPAT)
1,033 1,853 1,868 1,794 694 1,144 1,796 2,293 1,586 2,062 2,383
Normalized NOPAT Margin
12.68% 20.39% 21.97% 21.38% 9.32% 13.96% 26.01% 32.83% 25.97% 30.14% 35.83%
Pre Tax Income Margin
24.21% 8.61% 36.47% 9.47% -0.91% 10.40% 28.21% 23.10% 56.38% 25.56% 35.96%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
3.73 2.05 5.00 1.98 0.92 2.04 3.57 3.15 7.34 5.21 7.50
NOPAT to Interest Expense
1.43 2.48 2.41 2.22 0.84 1.39 2.37 3.05 2.92 4.97 6.48
EBIT Less CapEx to Interest Expense
3.16 1.55 4.66 1.69 0.64 1.73 3.24 2.79 6.71 4.39 7.07
NOPAT Less CapEx to Interest Expense
0.86 1.98 2.08 1.93 0.56 1.09 2.04 2.69 2.29 4.15 6.04
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
82.64% 118.14% 112.70% 150.06% 122.96% 67.83% 58.90% 54.57% 53.72% 64.04% 60.66%
Augmented Payout Ratio
82.64% 123.03% 112.70% 150.06% 122.96% 67.83% 58.90% 54.57% 53.72% 161.11% 174.82%

Frequently Asked Questions About Amgen's Financials

When does Amgen's financial year end?

According to the most recent income statement we have on file, Amgen's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Amgen's net income changed over the last 9 years?

In the past 9 years, Amgen's net income has ranged from $1.98 billion in 2017 to $8.39 billion in 2018, and is currently $4.09 billion as of their latest financial filing in 2024. Check out Amgen's forecast to explore projected trends and price targets.

What is Amgen's operating income?
Amgen's total operating income in 2024 was $7.26 billion, based on the following breakdown:
  • Total Gross Profit: $20.57 billion
  • Total Operating Expenses: $13.31 billion
How has Amgen revenue changed over the last 9 years?

Over the last 9 years, Amgen's total revenue changed from $21.66 billion in 2015 to $33.42 billion in 2024, a change of 54.3%.

How much debt does Amgen have?

Amgen's total liabilities were at $85.96 billion at the end of 2024, a 5.5% decrease from 2023, and a 98.2% increase since 2015.

How much cash does Amgen have?

In the past 9 years, Amgen's cash and equivalents has ranged from $3.24 billion in 2016 to $11.97 billion in 2024, and is currently $11.97 billion as of their latest financial filing in 2024.

How has Amgen's book value per share changed over the last 9 years?

Over the last 9 years, Amgen's book value per share changed from 37.23 in 2015 to 10.93 in 2024, a change of -70.6%.



This page (NASDAQ:AMGN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners